$INCY (+4.8% pre) Incyte taps Bill Meury as CEO https://t.co/uNPnIpX30r
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer $BMRA https://t.co/R3bBnaruKW
Bill Meury was CEO of Anthos when it was acquired by Novartis. Meury was CEO of Karuna when it was acquired by Bristol. Meury is now CEO of Incyte $INCY, and Julian Baker (largest shareholder) was elevated to Chairman. Hmmmm.....
Incyte Corp. said it has appointed Bill Meury as chief executive officer, effective immediately, succeeding Hervé Hoppenot, who will retire after a decade at the helm of the Wilmington, Delaware-based biotechnology company. Meury has developed a reputation for steering companies into high-value takeovers. He led Anthos Therapeutics prior to its acquisition by Novartis and earlier ran Karuna Therapeutics when it was bought by Bristol Myers Squibb. His track record positions him to guide Incyte as it seeks to reinvigorate growth in oncology and immunology drug development. Alongside the leadership change, Julian Baker—Incyte’s largest shareholder through Baker Bros. Advisors—was named chairman of the board. Incyte shares rose about 5% in pre-market trading after the announcement on Thursday.
